Lenabasum 20 mg

DRUG3 trials

Sponsors

Corbus Pharmaceuticals Inc.

Conditions

Cystic FibrosisDermatomyositisDiffuse Cutaneous Systemic Sclerosis

Phase 2

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

CompletedNCT03451045

Corbus Pharmaceuticals Inc.Cystic Fibrosis

Start: 2017-12-22End: 2020-06-17Updated: 2023-01-18

Phase 3

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

TerminatedNCT03398837

Corbus Pharmaceuticals Inc.Diffuse Cutaneous Systemic Sclerosis

Start: 2017-12-18End: 2020-12-21Updated: 2021-03-29

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

CompletedNCT03813160

Corbus Pharmaceuticals Inc.Dermatomyositis

Start: 2018-12-17End: 2021-10-05Updated: 2022-08-16

Related Papers

Diverse Lenabasum pathway activation in dermatomyositis patients’ blood

Scientific Reports2025-05-181 citations